EU promotes Marburg research: New hope for brain tumors!

EU promotes Marburg research: New hope for brain tumors!

Lauterbach, Deutschland - The University of Marburg can be happy: The European Union has funded a research project to combat glioblastomas with 1.3 million euros. This project, which is known as Percareglio and is managed by Jörg Bartsch, is intended to help develop tailor -made therapeutic approaches for one of the most aggressive forms of brain tumors. Full funding is necessary because standard therapy has not changed for over 15 years. A fact that shows an urgent need for action, because the median survival of patients with glioblastoma is less than 15 months, as in a current report of [health research-bmbf.de] (https://www.gesundheitsforschung-bmbf.de/de/iperglio-beserung-der-glioblastoma- treated- an--kombination-aus-immunomics-16892.php) is highlighted.

The ambitious Percareglio project uses the latest technologies, including artificial intelligence to analyze tumors on a molecular level. The aim is to determine the specific properties of the tumors and to check the effectiveness of already approved medication. The involvement of international research groups from Freiburg, Paris, Coimbra, Barcelona and Bucharest is doing research in a European context, which promotes the exchange of knowledge and experiences.

research and development in detail

The challenge in the treatment of glioblastomas should not be underestimated: the knowledge of the tumors has expanded through progress in immunotherapy, but these therapies are only 10-20 % of patients of long-term benefits. One reason for this could be the lack of suitable biomarkers that are decisive in diagnostics and therapy. Another key message of the report of [health research-bMBF.de] (https://www.gesundheitsforschung-bmbf.de/de/iperglio-verbesserung-der-glastoma- through-a-combination-out-immunomics-16892.php) is the need to gender and age-specific aspects and environmental factors in patients to be taken into account.

The Iperglio network study, in which 260 GLOBLASTOM patients take part, aims to capture these different factors in a comprehensive data integration using artificial intelligence. In this way, new, effective therapeutic approaches are to be developed that provide for a combination of immunotherapies with other treatments. Events on the active inclusion of patients and interest groups are also carried out to ensure that the results of the research benefit directly to the affected person.

New therapy approaches in the pipeline

The topic is also actively processed elsewhere: Under Mannheimischer Head, the Gloria study, which deals with a new active ingredient, olaptesed Pegol, in combination with radiation therapy. The messenger fabric CXCL12 is inhibited, which should counteract tumor regeneration after treatment. Initial results show promising approaches, but as always in medicine, further research is necessary to confirm the effectiveness. This is also evident in a report by [dkfz.de] (https://www.dkfz.de/aktuelles/pressemitteilungen/detail/neue therapy-therapy-mit-gelter- against-hochaggressive-hirnumore-2). In summary, it can be said that the latest developments in Glioblastom research bring a fresh wind to the often dark prognostic landscape in both Marburg and other German cities. It becomes visible that a strong team of scientists and clinics works hand in hand to offer the patient new hope. And who knows, maybe the next breakthrough is only one step away.